Transplant Cell Ther 2022 Dec 30
Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
Related Questions
New answer by Radiation Oncologist at Mayo Clinic (October 24, 2023)
Before answering this important question, I think that we, as Radiation Oncologists, should give serious consideration to moving past the terminology of "bridging radiation th...
New answer by Medical Oncologist at Memorial Sloan Kettering Cancer Center (November 15, 2023)
Chimeric antigen receptor (CAR) T-cell therapy has been approved by the US Food and Drug Administration and other regulatory agencies for patients with R/R DLBCL (including hi...